Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges

James M. Smith, Rachna Rastogi, Ryan S. Teller, Priya Srinivasan, Pedro M M Mesquita, Umadevi Nagaraja, Janet M. McNicholl, R. Michael Hendry, Chuong T. Dinh, Amy Martin, Betsy Herold, Patrick F. Kiser

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Topical preexposure prophylaxis interrupts HIV transmission at the site of mucosal exposure. Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application. However, modest or no protection was observed in clinical trials. Intravaginal rings (IVRs) may improve efficacy by providing long-term sustained drug delivery leading to constant mucosal antiretroviral concentrations and enhancing adherence. Although a few IVRs have entered the clinical pipeline, 100% efficacy in a repeated macaque vaginal challenge model has not been achieved. Here we describe a reservoir IVR technology that delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28 d. With four monthly ring changes in this repeated challenge model, TDF IVRs generated reproducible and protective drug levels. All TDF IVR-treated macaques (n = 6) remained seronegative and simian-HIV RNA negative after 16 weekly vaginal exposures to 50 tissue culture infectious dose SHIV162p3. In contrast, 11/12 control macaques became infected, with a median of four exposures assuming an eclipse of 7 d from infection to virus RNA detection. Protection was associated with tenofovir levels in vaginal fluid [mean 1.8 × 105 ng/mL (range 1.1 × 104 to 6.6 × 105 ng/mL)] and ex vivo antiviral activity of cervicovaginal lavage samples. These observations support further advancement of TDF IVRs as well as the concept that extended duration drug delivery devices delivering topical antiretrovirals could be effective tools in preventing the sexual transmission of HIV in humans.

Original languageEnglish (US)
Pages (from-to)16145-16150
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number40
DOIs
StatePublished - Oct 1 2013

Fingerprint

Tenofovir
Macaca
HIV
RNA Virus Infections
Foams and Jellies Vaginal Creams
Protective Agents
Reverse Transcriptase Inhibitors
Therapeutic Irrigation
Prodrugs
Pharmaceutical Preparations
Antiviral Agents

Keywords

  • Controlled drug delivery
  • Nonhuman primate
  • Pharmacokinetics
  • PrEP

ASJC Scopus subject areas

  • General

Cite this

Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. / Smith, James M.; Rastogi, Rachna; Teller, Ryan S.; Srinivasan, Priya; Mesquita, Pedro M M; Nagaraja, Umadevi; McNicholl, Janet M.; Hendry, R. Michael; Dinh, Chuong T.; Martin, Amy; Herold, Betsy; Kiser, Patrick F.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 40, 01.10.2013, p. 16145-16150.

Research output: Contribution to journalArticle

Smith, JM, Rastogi, R, Teller, RS, Srinivasan, P, Mesquita, PMM, Nagaraja, U, McNicholl, JM, Hendry, RM, Dinh, CT, Martin, A, Herold, B & Kiser, PF 2013, 'Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges', Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 40, pp. 16145-16150. https://doi.org/10.1073/pnas.1311355110
Smith, James M. ; Rastogi, Rachna ; Teller, Ryan S. ; Srinivasan, Priya ; Mesquita, Pedro M M ; Nagaraja, Umadevi ; McNicholl, Janet M. ; Hendry, R. Michael ; Dinh, Chuong T. ; Martin, Amy ; Herold, Betsy ; Kiser, Patrick F. / Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 40. pp. 16145-16150.
@article{b3ec2deb0cd94a479b1819a789749504,
title = "Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges",
abstract = "Topical preexposure prophylaxis interrupts HIV transmission at the site of mucosal exposure. Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application. However, modest or no protection was observed in clinical trials. Intravaginal rings (IVRs) may improve efficacy by providing long-term sustained drug delivery leading to constant mucosal antiretroviral concentrations and enhancing adherence. Although a few IVRs have entered the clinical pipeline, 100{\%} efficacy in a repeated macaque vaginal challenge model has not been achieved. Here we describe a reservoir IVR technology that delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28 d. With four monthly ring changes in this repeated challenge model, TDF IVRs generated reproducible and protective drug levels. All TDF IVR-treated macaques (n = 6) remained seronegative and simian-HIV RNA negative after 16 weekly vaginal exposures to 50 tissue culture infectious dose SHIV162p3. In contrast, 11/12 control macaques became infected, with a median of four exposures assuming an eclipse of 7 d from infection to virus RNA detection. Protection was associated with tenofovir levels in vaginal fluid [mean 1.8 × 105 ng/mL (range 1.1 × 104 to 6.6 × 105 ng/mL)] and ex vivo antiviral activity of cervicovaginal lavage samples. These observations support further advancement of TDF IVRs as well as the concept that extended duration drug delivery devices delivering topical antiretrovirals could be effective tools in preventing the sexual transmission of HIV in humans.",
keywords = "Controlled drug delivery, Nonhuman primate, Pharmacokinetics, PrEP",
author = "Smith, {James M.} and Rachna Rastogi and Teller, {Ryan S.} and Priya Srinivasan and Mesquita, {Pedro M M} and Umadevi Nagaraja and McNicholl, {Janet M.} and Hendry, {R. Michael} and Dinh, {Chuong T.} and Amy Martin and Betsy Herold and Kiser, {Patrick F.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1073/pnas.1311355110",
language = "English (US)",
volume = "110",
pages = "16145--16150",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "40",

}

TY - JOUR

T1 - Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges

AU - Smith, James M.

AU - Rastogi, Rachna

AU - Teller, Ryan S.

AU - Srinivasan, Priya

AU - Mesquita, Pedro M M

AU - Nagaraja, Umadevi

AU - McNicholl, Janet M.

AU - Hendry, R. Michael

AU - Dinh, Chuong T.

AU - Martin, Amy

AU - Herold, Betsy

AU - Kiser, Patrick F.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Topical preexposure prophylaxis interrupts HIV transmission at the site of mucosal exposure. Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application. However, modest or no protection was observed in clinical trials. Intravaginal rings (IVRs) may improve efficacy by providing long-term sustained drug delivery leading to constant mucosal antiretroviral concentrations and enhancing adherence. Although a few IVRs have entered the clinical pipeline, 100% efficacy in a repeated macaque vaginal challenge model has not been achieved. Here we describe a reservoir IVR technology that delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28 d. With four monthly ring changes in this repeated challenge model, TDF IVRs generated reproducible and protective drug levels. All TDF IVR-treated macaques (n = 6) remained seronegative and simian-HIV RNA negative after 16 weekly vaginal exposures to 50 tissue culture infectious dose SHIV162p3. In contrast, 11/12 control macaques became infected, with a median of four exposures assuming an eclipse of 7 d from infection to virus RNA detection. Protection was associated with tenofovir levels in vaginal fluid [mean 1.8 × 105 ng/mL (range 1.1 × 104 to 6.6 × 105 ng/mL)] and ex vivo antiviral activity of cervicovaginal lavage samples. These observations support further advancement of TDF IVRs as well as the concept that extended duration drug delivery devices delivering topical antiretrovirals could be effective tools in preventing the sexual transmission of HIV in humans.

AB - Topical preexposure prophylaxis interrupts HIV transmission at the site of mucosal exposure. Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application. However, modest or no protection was observed in clinical trials. Intravaginal rings (IVRs) may improve efficacy by providing long-term sustained drug delivery leading to constant mucosal antiretroviral concentrations and enhancing adherence. Although a few IVRs have entered the clinical pipeline, 100% efficacy in a repeated macaque vaginal challenge model has not been achieved. Here we describe a reservoir IVR technology that delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28 d. With four monthly ring changes in this repeated challenge model, TDF IVRs generated reproducible and protective drug levels. All TDF IVR-treated macaques (n = 6) remained seronegative and simian-HIV RNA negative after 16 weekly vaginal exposures to 50 tissue culture infectious dose SHIV162p3. In contrast, 11/12 control macaques became infected, with a median of four exposures assuming an eclipse of 7 d from infection to virus RNA detection. Protection was associated with tenofovir levels in vaginal fluid [mean 1.8 × 105 ng/mL (range 1.1 × 104 to 6.6 × 105 ng/mL)] and ex vivo antiviral activity of cervicovaginal lavage samples. These observations support further advancement of TDF IVRs as well as the concept that extended duration drug delivery devices delivering topical antiretrovirals could be effective tools in preventing the sexual transmission of HIV in humans.

KW - Controlled drug delivery

KW - Nonhuman primate

KW - Pharmacokinetics

KW - PrEP

UR - http://www.scopus.com/inward/record.url?scp=84885068247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885068247&partnerID=8YFLogxK

U2 - 10.1073/pnas.1311355110

DO - 10.1073/pnas.1311355110

M3 - Article

VL - 110

SP - 16145

EP - 16150

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 40

ER -